BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 31238876)

  • 21. The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression-Based Meta-Analysis.
    Stover DG; Coloff JL; Barry WT; Brugge JS; Winer EP; Selfors LM
    Clin Cancer Res; 2016 Dec; 22(24):6039-6050. PubMed ID: 27330058
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune-Phenotyping and Transcriptomic Profiling of Peripheral Blood Mononuclear Cells From Patients With Breast Cancer: Identification of a 3 Gene Signature Which Predicts Relapse of Triple Negative Breast Cancer.
    Foulds GA; Vadakekolathu J; Abdel-Fatah TMA; Nagarajan D; Reeder S; Johnson C; Hood S; Moseley PM; Chan SYT; Pockley AG; Rutella S; McArdle SEB
    Front Immunol; 2018; 9():2028. PubMed ID: 30254632
    [No Abstract]   [Full Text] [Related]  

  • 23. Mechanisms of tumor immune escape in triple-negative breast cancers (TNBC) with and without mutated BRCA 1.
    Engel JB; Honig A; Kapp M; Hahne JC; Meyer SR; Dietl J; Segerer SE
    Arch Gynecol Obstet; 2014 Jan; 289(1):141-7. PubMed ID: 23828443
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of sample-specific regulations using integrative network level analysis.
    Liu C; Louhimo R; Laakso M; Lehtonen R; Hautaniemi S
    BMC Cancer; 2015 Apr; 15():319. PubMed ID: 25928379
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Claudin 4 expression in triple-negative breast cancer: correlation with androgen receptors and Ki-67 expression.
    Abd-Elazeem MA; Abd-Elazeem MA
    Ann Diagn Pathol; 2015 Feb; 19(1):37-42. PubMed ID: 25456318
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer.
    Choi JE; Kang SH; Lee SJ; Bae YK
    Ann Surg Oncol; 2015 Jan; 22(1):82-9. PubMed ID: 25145503
    [TBL] [Abstract][Full Text] [Related]  

  • 27. L1CAM is expressed in triple-negative breast cancers and is inversely correlated with androgen receptor.
    Doberstein K; Milde-Langosch K; Bretz NP; Schirmer U; Harari A; Witzel I; Ben-Arie A; Hubalek M; Müller-Holzner E; Reinold S; Zeimet AG; Altevogt P; Fogel M
    BMC Cancer; 2014 Dec; 14():958. PubMed ID: 25510351
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In silico recognition of a prognostic signature in basal-like breast cancer patients.
    Conte F; Sibilio P; Grimaldi AM; Salvatore M; Paci P; Incoronato M
    PLoS One; 2022; 17(2):e0264024. PubMed ID: 35167614
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association between androgen receptor status and prognosis in triple negative breast cancer.
    Sunar V; T Dogan H; Sarici F; Ates O; Akin S; Baspinar B; Aksoy S; Altundag K
    J BUON; 2018; 23(5):1325-1330. PubMed ID: 30570854
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BRCA mutations cause reduction in miR-200c expression in triple negative breast cancer.
    Erturk E; Cecener G; Tezcan G; Egeli U; Tunca B; Gokgoz S; Tolunay S; Tasdelen I
    Gene; 2015 Feb; 556(2):163-9. PubMed ID: 25445393
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Six novel immunoglobulin genes as biomarkers for better prognosis in triple-negative breast cancer by gene co-expression network analysis.
    Hsu HM; Chu CM; Chang YJ; Yu JC; Chen CT; Jian CE; Lee CY; Chiang YT; Chang CW; Chang YT
    Sci Rep; 2019 Mar; 9(1):4484. PubMed ID: 30872752
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Triple negative status and BRCA mutations in contralateral breast cancer: a population-based study.
    Pellegrino B; Bella M; Michiara M; Zanelli P; Naldi N; Porzio R; Bortesi B; Boggiani D; Zanoni D; Camisa R; Neri TM; Pinto C; Musolino A
    Acta Biomed; 2016 May; 87(1):54-63. PubMed ID: 27163896
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Androgen receptor- and PIAS1-regulated gene programs in molecular apocrine breast cancer cells.
    Malinen M; Toropainen S; Jääskeläinen T; Sahu B; Jänne OA; Palvimo JJ
    Mol Cell Endocrinol; 2015 Oct; 414():91-8. PubMed ID: 26219822
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of triple-negative breast cancer radiosensitive gene signature and validation based on transcriptome analysis.
    Wushou A; Jiang YZ; Hou J; Liu YR; Guo XM; Shao ZM
    Breast Cancer Res Treat; 2015 Nov; 154(1):57-62. PubMed ID: 26476726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genes associated with histopathologic features of triple negative breast tumors predict molecular subtypes.
    Purrington KS; Visscher DW; Wang C; Yannoukakos D; Hamann U; Nevanlinna H; Cox A; Giles GG; Eckel-Passow JE; Lakis S; Kotoula V; Fountzilas G; Kabisch M; Rüdiger T; Heikkilä P; Blomqvist C; Cross SS; Southey MC; Olson JE; Gilbert J; Deming-Halverson S; Kosma VM; Clarke C; Scott R; Jones JL; Zheng W; Mannermaa A; ; Eccles DM; Vachon CM; Couch FJ
    Breast Cancer Res Treat; 2016 May; 157(1):117-31. PubMed ID: 27083182
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The exploration of contrasting pathways in Triple Negative Breast Cancer (TNBC).
    Narrandes S; Huang S; Murphy L; Xu W
    BMC Cancer; 2018 Jan; 18(1):22. PubMed ID: 29301506
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phosphorylation of androgen receptors at serine 515 is a potential prognostic marker for triple negative breast cancer.
    Roseweir AK; McCall P; Scott A; Liew B; Lim Z; Mallon EA; Edwards J
    Oncotarget; 2017 Jun; 8(23):37172-37185. PubMed ID: 28415597
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting the androgen receptor in triple-negative breast cancer.
    Gucalp A; Traina TA
    Curr Probl Cancer; 2016; 40(2-4):141-150. PubMed ID: 27816190
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Androgenic pathways in the progression of triple-negative breast carcinoma: a comparison between aggressive and non-aggressive subtypes.
    McNamara KM; Yoda T; Nurani AM; Shibahara Y; Miki Y; Wang L; Nakamura Y; Suzuki K; Yang Y; Abe E; Hirakawa H; Suzuki T; Nemoto N; Miyashita M; Tamaki K; Ishida T; Brown KA; Ohuchi N; Sasano H
    Breast Cancer Res Treat; 2014 Jun; 145(2):281-93. PubMed ID: 24715382
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Androgen receptor expression predicts different clinical outcomes for breast cancer patients stratified by hormone receptor status.
    Jiang HS; Kuang XY; Sun WL; Xu Y; Zheng YZ; Liu YR; Lang GT; Qiao F; Hu X; Shao ZM
    Oncotarget; 2016 Jul; 7(27):41285-41293. PubMed ID: 27285752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.